Alpha 2.0
Login Register
» Articles » PMID: 35131172

Hypervitaminosis A with Fulminant Secondary Intracranial Hypertension Following Personalized Medicine-based Elexacaftor/Tezacaftor/Ivacaftor Initiation in a Preadolescent with Cystic Fibrosis

Overview
Journal J Cyst Fibros
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2022 Feb 8
PMID 35131172
Authors
Benjamin L Wisniewski
Shawn C Aylward
Catherine O Jordan
Benjamin T Kopp
Grace R Paul
Affiliations
Soon will be listed here.
Citing Articles

Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis - a real-life insight.

Fabricius D, Knieling T, Zurmuehl N, Makedon L, Freihorst J, Schmidt H Mol Cell Pediatr. 2024; 11(1):4.

PMID: 38717689 PMC: 11078909. DOI: 10.1186/s40348-024-00178-6.

The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis.

Hergenroeder G, Faino A, Bridges G, Bartlett L, Cogen J, Green N J Cyst Fibros. 2023; 22(6):1048-1053.

PMID: 37563007 PMC: 10843772. DOI: 10.1016/j.jcf.2023.08.002.

Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.

Olivier M, Kavvalou A, Welsner M, Hirtz R, Strassburg S, Sutharsan S Front Pharmacol. 2023; 14:1176815.

PMID: 37229253 PMC: 10203630. DOI: 10.3389/fphar.2023.1176815.

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.

Tummler B Front Pharmacol. 2023; 14:1158207.

PMID: 37025483 PMC: 10072268. DOI: 10.3389/fphar.2023.1158207.

Elexacaftor/tezacaftor/ivacaftor-real-world clinical effectiveness and safety. A single-center Portuguese study.

Lopes K, Custodio C, Lopes C, Bolas R, Azevedo P J Bras Pneumol. 2023; 49(2):e20220312.

PMID: 36820745 PMC: 9970613. DOI: 10.36416/1806-3756/e20220312.